🎓Nurse Corps Scholarship Program OMB Review Notice
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
Learn More🏥Medicare and Medicaid 2026 Updates
The regulatory document outlines updates to the Home Health Prospective Payment System (HH PPS) and the Quality Reporting Program for 2026, alongside changes to the Durable Medical Equipment Competitive Bidding Program. These updates aim to streamline compliance and enhance service delivery in the healthcare sector, impacting various stakeholders, including providers and patients.
Learn More📋National Sample Survey of Registered Nurses
The Department of Commerce is seeking public comments on the National Sample Survey of Registered Nurses, aimed at collecting data to evaluate the characteristics and distribution of registered nurses in the U.S. The initiative addresses the evolving dynamics of the nursing workforce and includes modifications to the survey methods and content for the next collection cycle.
Learn More💊FDA Determines Heparin Sodium Products Not Withdrawn for Safety
The Food and Drug Administration (FDA or Agency) has determined that HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (heparin sodium) injectable, 5,000 units/100 milliliters (mL); HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (heparin sodium) injectable, 5,000 units/100 mL; HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (heparin sodium) injectable, 10,000 units/100 mL; and HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (heparin sodium) injectable, 5,000 units/100 mL under new drug application (NDA) 019802 were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) that refer to these products if all other legal and regulatory requirements are met.
Learn More💊FDA Notice on LUMISIGHT Patent Extension Review Period
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUMISIGHT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Learn More📊Proposed Information Collection for NCI Data Sharing Forms
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide an opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Learn More🏥Proposed Medicaid Information Collection Activities and Business Impact
On May 28, 2010, the Office of Management and Budget (OMB) issued Paperwork Reduction Act (PRA) guidance related to the "generic" clearance process. Generally, this is an expedited process by which agencies may obtain OMB's approval of collection of information requests that are "usually voluntary, low-burden, and uncontroversial collections," do not raise any substantive or policy issues, and do not require policy or methodological review. The process requires the submission of an overarching plan that defines the scope of the individual collections that would fall under its umbrella. This Federal Register notice seeks public comment on one or more of our collection of information requests that we believe are generic and fall within the scope of the umbrella. Interested persons are invited to submit comments regarding our burden estimates or any other aspect of this collection of information, including: the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Learn More💊FDA Notice on Patent Extension for IQIRVO Drug Review Period
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IQIRVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Learn More⚖️FINRA Accelerates Arbitration for Elderly and Health-Affected Parties
The FINRA proposed rule change aims to accelerate arbitration proceedings for parties aged 70 and over or those with specific health conditions. This initiative seeks to ensure that these individuals can participate meaningfully in the arbitration process, enhancing outcomes reflective of their claims while maintaining flexibility for arbitrators in scheduling and case management.
Learn More💊FDA Announces Regulatory Review Determination for OHTUVAYRE
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OHTUVAYRE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.
Learn More